SG11202101920WA - Composition for eradicating helicobacter pylori - Google Patents

Composition for eradicating helicobacter pylori

Info

Publication number
SG11202101920WA
SG11202101920WA SG11202101920WA SG11202101920WA SG11202101920WA SG 11202101920W A SG11202101920W A SG 11202101920WA SG 11202101920W A SG11202101920W A SG 11202101920WA SG 11202101920W A SG11202101920W A SG 11202101920WA SG 11202101920W A SG11202101920W A SG 11202101920WA
Authority
SG
Singapore
Prior art keywords
composition
helicobacter pylori
eradicating helicobacter
eradicating
pylori
Prior art date
Application number
SG11202101920WA
Inventor
Bong Tae Kim
Dongkyu Kim
Eun Ji Kim
Ji Won Lee
Kyeongmin Oh
Ahrong Kim
Geun Seog Song
Shin-Young Ryu
Eun Kyung Kim
Naree Shin
Hyun Ji Kang
Jae Min Kim
Yu-Gyeong Park
Haneul Jeong
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of SG11202101920WA publication Critical patent/SG11202101920WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11202101920WA 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori SG11202101920WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29
PCT/KR2019/011017 WO2020045992A1 (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Publications (1)

Publication Number Publication Date
SG11202101920WA true SG11202101920WA (en) 2021-04-29

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101920WA SG11202101920WA (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Country Status (19)

Country Link
US (1) US20210196685A1 (en)
EP (1) EP3843723A4 (en)
JP (1) JP7189327B2 (en)
KR (1) KR20200026118A (en)
CN (1) CN112638378A (en)
AR (1) AR116026A1 (en)
AU (1) AU2019328903B2 (en)
BR (1) BR112021003578A2 (en)
CA (1) CA3107624C (en)
EA (1) EA202190622A1 (en)
GE (1) GEP20227431B (en)
JO (1) JOP20190201A1 (en)
MX (1) MX2021002278A (en)
MY (1) MY195494A (en)
PH (1) PH12021550385A1 (en)
SG (1) SG11202101920WA (en)
UA (1) UA126993C2 (en)
UY (1) UY38348A (en)
WO (1) WO2020045992A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180094A1 (en) 2017-10-18 2019-04-18 Hk Inno N Corp Heterocyclic compound as a protein kinase inhibito
CN113939293A (en) * 2019-04-18 2022-01-14 托马斯·朱利叶斯·波洛迪 Compositions and methods for treating, ameliorating and preventing helicobacter pylori infection
WO2024210689A1 (en) * 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 Salt of benzimidazole derivative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
CA2631880C (en) * 2005-12-19 2011-03-29 Pfizer Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
CN101015694A (en) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 Compound oral preparation for treating spirobacillus infection of pylorus
SI3305291T1 (en) * 2015-06-08 2021-08-31 Hk Inno.N Corporation Uses of benzimidazole derivative for nocturnal acid breakthrough
WO2017125912A1 (en) * 2016-01-21 2017-07-27 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (en) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 Acid addition salts of (S)-4-(5,7-difluorochroman-4-yloxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-carboxamide
CN108379258B (en) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 Application of daphnetin in resisting helicobacter pylori

Also Published As

Publication number Publication date
US20210196685A1 (en) 2021-07-01
WO2020045992A1 (en) 2020-03-05
UA126993C2 (en) 2023-03-01
BR112021003578A2 (en) 2021-05-18
JP2021535910A (en) 2021-12-23
CA3107624A1 (en) 2020-03-05
AU2019328903A8 (en) 2021-05-27
EA202190622A1 (en) 2021-06-10
CN112638378A (en) 2021-04-09
JOP20190201A1 (en) 2020-02-29
PH12021550385A1 (en) 2021-09-20
GEP20227431B (en) 2022-10-25
MY195494A (en) 2023-01-26
AU2019328903A1 (en) 2021-04-29
CA3107624C (en) 2023-10-03
EP3843723A4 (en) 2022-06-29
UY38348A (en) 2020-03-31
MX2021002278A (en) 2021-08-11
KR20200026118A (en) 2020-03-10
EP3843723A1 (en) 2021-07-07
AR116026A1 (en) 2021-03-25
AU2019328903B2 (en) 2023-01-05
JP7189327B2 (en) 2022-12-13

Similar Documents

Publication Publication Date Title
GB201811312D0 (en) Compositions
GB2586745B (en) Compositions
PL3634444T3 (en) Compositions for use in the treatment of helicobacter pylori
SG11202101920WA (en) Composition for eradicating helicobacter pylori
SG11202009259VA (en) Compositions
GB201810492D0 (en) Composition
GB201911609D0 (en) Compositions
GB2575549B (en) Chocolate composition
GB201811100D0 (en) Composition
ZA202204622B (en) Polypeptide and polypeptide composition for inhibiting and eliminating biofilm formed by helicobacter pylori
IL289424A (en) Extended release gastroretentive formulation against helicobacter pylori
ZA202100515B (en) Curcuminoid compositions
PT3765379T (en) Compositions
EP3658590C0 (en) Photoinitiators for light-curable compositions
ZA202006762B (en) Improved wetting composition
GB201812145D0 (en) Composition
GB201804434D0 (en) Composition
PL3870195T3 (en) New probiotics useful for eradicating helicobacter pylori infection
GB201810024D0 (en) Composition
GB201809123D0 (en) Composition
GB201805676D0 (en) Compositions
GB201801425D0 (en) Compositions
GB201801596D0 (en) Composition
AU2018902387A0 (en) Helicobacter pylori immunotherapy
GB201914617D0 (en) Nutraceutical composition